Fundraising FoxSightStream Biotherapeutics
Walpole, US · Founded 2020 · Delaware corporation
Find your way into SightStream Biotherapeutics
Each arrow is one introduction. Sign up to fill in the first one.
274 people can intro you to Jason
Ask Gene Mack to introduce you to Jason Werner
You →Gene · together at Nicox →Jason
Sign up to find every way you can get introduced to SightStream Biotherapeutics
- Your email: who you already know at SightStream Biotherapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the SightStream Biotherapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
DN
David NeafusExecutive
JW
Jason WernerExecutiveHe has held leadership roles in business development and commercial strategy in the life sciences sector, with experience spanning drug development, rare disease, ophthalmology, and biotechnology commercialization.
RD
Reza DanaNamed on SEC filing
JZ
Jiagang ZhaoNamed on SEC filing
Board
SW
Samuel WuBoard director
WX
Wenkai XiangBoard director
Reported raises · per SEC filings
Form D private placements$5.1M disclosed across 3 of 4 rounds · 2022–2025
▶$1.8MraisedOct 2025 · 9 investors · BiotechnologyRule 506(b)
▶$1.8MraisedOct 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Samuel WuDirector
- Wenkai XiangDirector
- David NeafusExecutive Officer
- Reza DanaDirector
- Jason WernerExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedAug 2023 · 2 investors · BiotechnologyRule 506(b)
▶$250KraisedAug 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason WernerExecutive Officer, Director
- Jiagang ZhaoDirector
- David NeafusExecutive Officer
- Reza DanaDirector
- Offering amount
- $1.3M
- Amount sold
- $250K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3.1MraisedJun 2023 · 21 investors · BiotechnologyRule 506(b)
▶$3.1MraisedJun 2023 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jiagang ZhaoDirector
- Reza DanaDirector
- David NeafusExecutive Officer
- Jason WernerExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3.1M
- Proceeds to insiders
- $300K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2022 · 18 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJun 2022 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Reza DanaDirector
- David NeafusExecutive Officer
- Jason WernerExecutive Officer, Director
- Jiagang ZhaoDirector
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has SightStream Biotherapeutics raised?
- SightStream Biotherapeutics has disclosed $5.1M raised across 3 of its 4 known rounds.
- Where is SightStream Biotherapeutics headquartered?
- SightStream Biotherapeutics is headquartered in Walpole, US.